IMARA Inc. (IMRA)
| Market Cap | 31.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -54.05M |
| Shares Out | 26.29M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,645 |
| Open | 1.17 |
| Previous Close | 1.16 |
| Day's Range | 1.16 - 1.23 |
| 52-Week Range | 0.97 - 5.10 |
| Beta | 1.98 |
| Analysts | Sell |
| Price Target | 1.22 (+3.4%) |
| Earnings Date | Aug 5, 2022 |
About IMRA
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2"related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorp... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IMRA stock is "Sell." The 12-month stock price forecast is 1.22, which is an increase of 3.39% from the latest price.
News
What Makes IMARA Inc. (IMRA) a New Buy Stock
IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read Why Imara Shares Are Falling Today
Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. Data...
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease...
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat popula...
Imara Reports Full Year 2021 Financial Results and Business Highlights
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferin...
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Imara To Start Testing Tovinontrine In Heart Failure Patients
The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to initia...
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Fail...
Expanding patient base and potential of Imara's small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
Imara Inc (NASDAQ: IMRA) has announced a change to the primary endpoint for the Ardent Phase 2 trial of tovinontrine (IMR-687) in sickle cell disease. Imara is a biopharmaceutical company focused on the...
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cel...
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation
7 Penny Stocks to Book Profits on Before 2022
Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.
Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose
Imara Inc (NASDAQ: IMRA) has announced data from a pre-specified interim analysis from its Forte Phase 2b trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia. S...
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dep...
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented
Imara to Participate in Upcoming Investor Conferences
SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference
Imara to Present at Upcoming Investor Conferences
Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Con...
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sick...
Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout no...
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
The 5 biggest insider stock buys of last week
Here are the five companies that saw the biggest combined stock purchases from insiders during the week ended July 16.